Occurrence of subacute cutaneous lupus erythematosus after treatment with fluorouracil and capecitabine

Journal of the American Academy of Dermatology

Volumn 59, Issue 2 SUPPL., 2008, Pages

  Weger, Wolfgang ^a   Kränke, Birger ^a   Gerger, Armin ^a   Salmhofer, Wolfgang ^a   Aberer, Elisabeth ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; RO ANTIBODY; STEROID;

AGED; ARTHRALGIA; ARTICLE; CASE REPORT; CLINICAL FEATURE; DRUG WITHDRAWAL; ERYTHEMA; FEMALE; FEVER; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MULTIPLE CYCLE TREATMENT; MYALGIA; PHOTOSENSITIVITY; PRIORITY JOURNAL; PUNCH BIOPSY; SKIN BIOPSY; SKIN LUPUS ERYTHEMATOSUS; STOMACH CANCER; SYMPTOM;

ACUTE DISEASE; ADMINISTRATION, ORAL; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; DEOXYCYTIDINE; FATAL OUTCOME; FEMALE; FLUOROURACIL; HUMANS; LUPUS ERYTHEMATOSUS, CUTANEOUS; SEVERITY OF ILLNESS INDEX; STEROIDS; STOMACH NEOPLASMS;

EID: 46749142088     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2007.06.040     Document Type: Article

References (14)

1. Walko C.M., and Lindley C. Capecitabine: a review. Clin Ther 27 (2005) 23-44
2. Ajani J.A. Evolving chemotherapy for advanced gastric cancer. Oncologist 10 Suppl (2005) 49-58
3. Milano G., Ferrero J.M., and Francois E. Comparative pharmacology of oral fluoropyrimidines: a focus on pharmacokinetics, pharmacodynamics and pharmacomodulation. Br J Cancer 91 (2004) 613-617
4. Lewis K.G., Lewis M.D., Robinson-Bostom L., and Pan T.D. Inflammation of actinic keratoses during capecitabine therapy. Arch Dermatol 140 (2004) 367-368
5. Sontheimer R.D. Subacute cutaneous lupus erythematosus: 25-year evolution of a prototypic subset (subphenotype) of lupus erythematosus defined by characteristic cutaneous, pathological, immunological, and genetic findings. Autoimmun Rev 4 (2005) 253-263
6. McKay D.A., Schofield O.M., and Benton E.C. Terbinafine-induced subacute cutaneous lupus erythematosus. Acta Derm Venereol 84 (2004) 472-474
7. Pramatarov K.D. Drug-induced lupus erythematosus. Clin Dermatol 16 (1998) 367-377
8. Dudley K., Micetich K., and Massa M.C. Erythema with features of seborrheic dermatitis and lupus erythematosus associated with systemic 5-fluorouracil. Cutis 39 (1987) 64-66
9. Kluger N., Bessis D., and Guillot B. Chronic cutaneous lupus flare induced by systemic 5-flurouracil. J Dermatol Treat 17 (2006) 51-53
10. Moazzam N., Malik A.A., Mehdi S.A., and Potti A. Fluorouracil induced exacerbation of systemic lupus erythematosus. J Clin Oncol 20 (2002) 3032-3034
11. Yoshimasu T., Hiroi A., Uede K., and Furukawa F. Discoid lupus erythematosus (DLE)-like lesions induced by uracil-tegafur (UFT). Eur J Dermatol 11 (2001) 54-57
12. Adachi A., Nagai H., and Horikawa T. Anti-SSA/Ro antibody as a risk factor for fluorouracil-induced drug eruptions showing acral erythema and discoid-lupus erythematosus-like lesions. Dermatology 214 (2007) 85-88
13. Chaudhry S.I., Murphy L.A., and White I.R. Subacute cutaneous lupus erythematosus: a paraneoplastic dermatosis?. Clin Exp Dermatol 30 (2005) 655-658
14. Yoshimasu T., Nishide T., Seo N., Hiroi A., Ohtani T., Uede K., et al. Susceptibility of T cell receptor-alpha chain knock-out mice to ultraviolet B light and fluorouracil: a novel model for drug induced cutaneous lupus erythematosus. Clin Exp Immunol 136 (2004) 245-254